Flucloxacilina Noridem (Flucloxacillin)

Flucloxacilina Noridem is indicated for infections that are known or suspected to be caused by penicillin‑ase‑producing Gram‑positive bacteria, especially Staphylococcus aureus.

• Skin and soft tissue infections such as cellulitis, impetigo, and wound infections.
• Bone and joint infections including osteomyelitis and septic arthritis.
• Respiratory tract infections like community‑acquired pneumonia caused by susceptible strains.
• Staphylococcal infections of the bloodstream or prosthetic devices.
• Surgical prophylaxis where penicillin‑resistant staphylococci are a concern.

Adverse reactions to flucloxacillin are generally mild and reversible, but serious events can occur and should be promptly recognized and managed.

Common

• Diarrhea or loose stools.
• Nausea and occasional vomiting.
• Skin rash or mild itching.
• Elevated liver enzymes without symptoms.
• Headache or dizziness.
• Metallic taste in the mouth.

Serious

• Severe allergic reactions such as anaphylaxis or angioedema.
• Hepatotoxicity presenting as jaundice, hepatitis, or cholestasis.
• Blood disorders including neutropenia or thrombocytopenia.
• Acute interstitial nephritis leading to renal impairment.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Flucloxacilina Noridem, clinicians should evaluate patient history and laboratory results to minimize risk of adverse outcomes.

• Assess liver function; flucloxacillin may cause cholestatic hepatitis, especially with prolonged therapy.
• Review renal function; dose adjustment may be needed in severe impairment.
• Obtain a detailed allergy history, particularly prior reactions to penicillins or cephalosporins.
• Use caution in patients with a history of jaundice, hepatitis, or biliary disease.
• Avoid use in newborns and premature infants due to limited safety data.
• Monitor complete blood count during long‑term treatment for possible neutropenia or thrombocytopenia.
• Consider alternative agents in patients receiving oral contraceptives, as flucloxacillin can reduce efficacy.

Flucloxacilina Noridem can alter the pharmacokinetics of several drugs; awareness of these interactions helps prevent therapeutic failure or toxicity.

Avoid

• Oral contraceptives containing estrogen or progestin, as flucloxacillin may increase hormone metabolism and reduce contraceptive effectiveness.
• Methotrexate, because flucloxacillin can decrease renal clearance and raise methotrexate levels, raising toxicity risk.
• Warfarin, where flucloxacillin may potentiate anticoagulant effect and increase INR.

Use with caution

• Antacids or proton pump inhibitors that contain aluminum or magnesium, which may reduce flucloxacillin absorption if given orally.
• Rifampicin, a potent enzyme inducer that can lower flucloxacillin concentrations.
• Cyclosporine, as flucloxacillin may increase cyclosporine levels and require monitoring.